Novo Nordisk A/S (NONOF) is expected to report earnings on Wednesday, November 4, 2026, after the close. Consensus EPS estimate is $0.77.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $0.77 | $0.94 | +22.8% | $11.96B |
| 2026-05-06 | FY2026 Q1 | $0.93 | $1.02 | +10.3% | $10.80B |
| 2024-09-30 | FY2024 Q3 | $0.90 | $0.92 | +2.5% | $10.68B |
| 2024-06-30 | FY2024 Q2 | $0.70 | $0.65 | -7.0% | $9.80B |
| 2024-03-31 | FY2024 Q1 | $0.68 | $0.72 | +6.8% | $9.72B |
| 2024-01-31 | FY2023 Q4 | $0.68 | $0.72 | +6.8% | $9.72B |
| 2022-12-31 | FY2022 Q4 | $0.84 | $0.88 | +3.8% | $6.95B |
| 2022-09-30 | FY2022 Q3 | $0.82 | $0.84 | +2.2% | $5.97B |
NONOF has beaten consensus EPS in 7 of its last 8 reported quarters.
See NONOF on the live calendar →